<DOC>
	<DOC>NCT00394927</DOC>
	<brief_summary>The purpose of the survey is to explore through a structured interview and patient examination the rate and distribution of neurological and systemic adverse effects related to antiepileptic treatment. Adverse effects and considerations to modify the therapy will be assessed in pediatric and adult patients with controlled as well as uncontrolled epilepsy with different seizure types</brief_summary>
	<brief_title>Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Male and female patients from the age of 4 years Confirmed diagnosis of epilepsy requiring AED treatment Patients already receiving daily AED treatment as a monotherapy or a polytherapy with maximum 2 AEDs within the terms of marketing authorization with the following medications: Carbamazepine, Clobazam, Clonazepam, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Phenobarbital, Phenytoin, Pregabalin, Tiagabine, Topiramate, Valproate, Zonisamide Treatment must be stable for at least 3 months prior to assessment Absence of other severe and/or uncontrolled symptomatic chronic illness</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Non-Interventional</keyword>
	<keyword>Surveillance</keyword>
	<keyword>Adverse Effects</keyword>
	<keyword>AntiEpileptic Drug treatment</keyword>
</DOC>